Lineage Cell Therapeutics, INC Form 4 insider transactions

Neal C. Bradsher, a Director and 10% Owner of Lineage Cell Therapeutics, Inc., reported transactions involving stock options.

Anula Jayasuriya, a Director at Lineage Cell Therapeutics, Inc., acquired 125,000 stock options.

Michael H. Mulroy, a Director at Lineage Cell Therapeutics, Inc., acquired 125,000 stock options with an exercise price of $1.30, vesting on July 1, 2027.

Lineage Cell Therapeutics' President and CEO, Brian M. Culley, has filed a Form 4 indicating a planned purchase of 15,000 common shares.

Lineage Cell Therapeutics' President and CEO, Brian M. Culley, was granted 3.25 million employee stock options with an exercise price of $1.84.

Lineage Cell Therapeutics' Chief Financial Officer, Jill Ann Howe, was granted 1,050,000 employee stock options with an exercise price of $1.84.

Lineage Cell Therapeutics' General Counsel and Secretary, George A. Samuel III, was granted 900,000 employee stock options with an exercise price of $1.84.

Lineage Cell Therapeutics CEO Brian M. Culley acquired 31,250 common shares through RSU vesting, with 12,869 shares withheld for taxes.

Lineage Cell Therapeutics' General Counsel, George A. Samuel III, acquired shares through RSU vesting and simultaneously disposed of shares for tax obligations.

Lineage Cell Therapeutics CEO Brian M. Culley reported the vesting of 8,925 restricted stock units and the withholding of 334 shares for tax purposes.

Lineage Cell Therapeutics' General Counsel, George A. Samuel III, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Lineage Cell Therapeutics, Inc. has granted 75,000 stock options to Director and 10% Owner Neal C. Bradsher as part of his director compensation, aligning his interests with shareholder value.

Lineage Cell Therapeutics, Inc. Director Dipti Amin was granted 75,000 stock options with an exercise price of $0.8977, vesting by July 1, 2026.

Lineage Cell Therapeutics, Inc. Director Anula Jayasuriya was granted 75,000 stock options with an exercise price of $0.8977, vesting on the earlier of July 1, 2026, or the next annual shareholder meeting.

Lineage Cell Therapeutics, Inc. Director Angus C. Russell was granted 75,000 stock options with an exercise price of $0.8977, vesting on the earlier of July 1, 2026, or the next annual shareholder meeting.

Lineage Cell Therapeutics, Inc. Director Michael H. Mulroy was granted 75,000 stock options with an exercise price of $0.8977, vesting by July 2026.

Deborah J. Andrews, a Director at Lineage Cell Therapeutics, Inc., was granted 75,000 stock options with an exercise price of $0.8977, vesting by July 1, 2026.

Lineage Cell Therapeutics' CEO, Brian M. Culley, reports the acquisition of 2.3 million employee stock options.

Lineage Cell Therapeutics' CFO, Jill Ann Howe, was granted 750,000 employee stock options on March 10, 2025, according to a Form 4 filing.

George A. Samuel III, General Counsel and Secretary of Lineage Cell Therapeutics, was granted stock options to purchase 750,000 common shares.

General Counsel George A. Samuel III reports the vesting of restricted stock units and subsequent share transactions.

Brian M. Culley, President and CEO of Lineage Cell Therapeutics, reports the vesting of restricted stock units and subsequent share withholding for tax obligations.

Broadwood Partners, L.P. has acquired 7,894,737 common shares and warrants in Lineage Cell Therapeutics for $6 million, following shareholder approval.

Lineage Cell Therapeutics' Chief Financial Officer, Jill Howe, purchased 15,000 shares of the company's common stock at an average price of $0.59 per share.

Lineage Cell Therapeutics' General Counsel, George A. Samuel III, purchased 15,000 common shares at $0.60 per share on November 26, 2024.

Michael H. Mulroy, a director at Lineage Cell Therapeutics, purchased 40,000 common shares at a price of $0.566 per share.

Lineage Cell Therapeutics' CEO, Brian M. Culley, purchased 40,000 common shares at an average price of $0.60 per share.

Jill Ann Howe, CFO of Lineage Cell Therapeutics, reports acquiring 10,500 common shares at $0.89 per share on August 16, 2024.

Michael H. Mulroy, a director of Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024, exercisable at $0.9541 per share.

Director Angus C. Russell acquires 75,000 stock options in Lineage Cell Therapeutics.